GSK Vaccines
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 2 disclosed transactions, GSK Vaccines concentrates its licensing activity in Cardiovascular, Other. GSK Vaccines pays a 0.70x discount to market median. Their most common deal structure is Option, with an average disclosed value of $6.7B. Most recent activity: 2025.
Pipeline coverage & gaps
GSK Vaccines has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| OptionPrimary | 1 | $500M | $12.0B |
| LicensePrimary | 1 | — | $1.3B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2025 | PDE3/4 inhibitor (COPD) plus 11 additional programs | Hengrui Pharma | COPD | unknown | $500M | $12.0B |
| 2024 | HS-20089 | Hansoh | — | unknown | — | $1.3B |
How this is computed
For each GSK Vaccines deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 0.674, clamped to [0.7, 1.5].